A comprehensive view of Amneal Pharmaceuticals LLC. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Amneal launches injectable Alymsys bevacizumab-maly biosimilar in US to treat various types of cancer in adults; the drug, developed with Spanish biopharma firm mAbxience, references Genetech’s Avastin and is first Amneal generic drug in US
Published: October 07, 2022 by Mondaq Business Briefing
Amneal recalls 13 lots of Lorazepam oral concentrate, USP 2mg/mL in individual cartons due to a defect on the dropper markings; product has code NDC 65162-687-84 and contains 30mL amber glass bottle
Published: September 14, 2022 by States News Service
Sandoz, Amneal, Rhodes join Teva in nationwide generic Adderall shortage as demand spikes; the firms make over half of all the generic extended-release version of the drug in US, where federal government limits amount each company can make
Published: August 30, 2022 by FiercePharma
Amneal receives FDA ANDA approval for four generic products including Vasopressin injection, oral Famotidine, Atropine sulfate 1% ophthalmic solution, Clindamycin phosphate topical gel USP 1% 75 mL; Amneal targets 20-30 new generic launches annually
Published: August 15, 2022 by Business Wire
Amgen and Kashiv Biosciences get US approval for Fylnetra, a biosimilar to Amgen’s injectable Neulasta pegfilgrastim to treat neutropenia resulting from chemotherapy; in 12 months ending March 2022, Neulasta biosimilars had US sales of US$1B
Published: June 07, 2022 by SeeNews Pharmaceuticals (

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count